Published on : Apr 20, 2016
ALBANY, New York, April 20, 2016: The report covers diagnostic contract documents, agreement terms, agreement structure, top cancer diagnostic deals by value, and the most active cancer diagnostics dealmakers. The report provides access to deals and the contract documents of about 1,170 cancer diagnostic deals.
The report answers several important questions that a reader may have, such as the exact rights granted and optioned in deals, what is actually granted by the agreement to the partnering company, the payment structure of the deal, the exclusivity of the deal, how the payments are audited, details of the deal terms, how IPRs are owned and handled, management of publication and confidentiality, the state under which the deal can be terminated, and how disputes are resolved.
Other queries answered in the report include the jurisdiction on which the company insists for the agreement’s legal standing, the boilerplate clauses the company emphasizes upon, the boilerplate clauses that appear to differ from deal to deal or partner to partner, the responsibility for commercialization, what happens when there is a change in ownership, and the sublicensing and subcontracting provisions that have been agreed upon.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=686344
The report benefits a reader by providing an in-depth analysis of cancer diagnostic deal trends since 2010. The reader gets access to data about upfront payments, headline data, royalty data, and milestone payments. Details about the cancer diagnostics contracts entered into by the leading biopharma companies and terms included in the partnering agreement have been given with examples. The study contains the details of the key deal terms that companies have agreed to in their previous deals. The study includes details of the latest cancer diagnostics agreements that have been announced in the life sciences field since 2010.
A comprehensive overview of the cancer diagnostics deal trends, top deal values, key players, financial details, and an understanding of why, how, and under what conditions the companies have entered into partnering deals is presented in the report. The report presents financial deal term values for cancer diagnostic deals by headline, milestone payments, value, royalties, and upfront payments, thus helping a reader understand and benchmark the financial value of deals.
The highlight of the report is the online deal records of the actual cancer diagnostics deals, which are revealed by the deal parties in the directory format, by company name, deal type, stage of development, therapy focus, and type of technology. This method makes the data easy to refer to for the readers. Furthermore, each deal record contains a link to an online version of the deal.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org